Tanner Pharma has announced the signing of a distribution agreement with Nephcentric, a developer and marketer of evidence based therapeutic options for people with kidney disease and metabolic disorders. The agreement names Tanner as a distributor of ure-Na (Urea 15g) in areas outside of the United States, Canada, and the Middle East where the product is not yet registered. ure-Na (Urea 15g) is a Medical Food for the management of hyponatremia.
The distribution will be managed by TannerGAP, a wholly owned subsidiary of Tanner Pharma Group. TannerGAP offers turnkey global access solutions for the distribution of products from markets of supply to markets of demand.
“We are excited to work with Nephcentric on a global level to provide ure-NA access to patients in need,” Maryori Alvarenga, Managing Director of US and Global Director for TannerGAP said.
“We are looking forward to our partnership with Tanner to help expand our reach beyond North America. Our partnership with Tanner will help more patients in need gain access to our cost-effective, evidence-based therapeutic options,” Caroline Von Scheven, Operations Lead for Nephcentric said.